GLP-1 Receptor Agonists in Overweight and Obese Individuals With Type 1 Diabetes Using an Automated Insulin Delivery Device: A Real-World Study
Authors' conclusion
Glucagon-like peptide-1 receptor agonist as add-on therapy for six months in individuals with obesity and AID-treated T1D led to considerable weight loss and a reduction in insulin dose.
Study context
- Population
- Overweight and obese individuals with T1D treated with automated insulin delivery (AID) and off-label GLP-1 RA for ≥6 months, Steno Diabetes Center Copenhagen, Denmark, January 2017–May 2024; median age 42 (range 24–60) years
- Participants
- 19 participants
- Outcome
- Change in body weight and total daily insulin dose
- Follow-up
- Six months
Methodological detailsreal-world, single-centre, off-label GLP-1 RA
- Real-world
- Single-centre
- Off-label GLP-1 RA
Main finding
As reported in the abstract
six months
Body weight change, median (range)
−11%
−22% to −3%P = .001
Total daily insulin dose change, median (range)
−15.1 (−32.5 to −8.2) IU
P = .004
Observational data: associations, not effects.
Further findings
Baseline characteristics at GLP-1 RA initiation, median (range)
- Hemoglobin A1c (HbA1c)
- 7.3% (6.1%-8.7%); 56 (43-72) mmol/mol
- Body weight
- 91.5 (78.0-115.0) kg
- BMI
- 35.4 (27.0-42.0) kg/m²
- TIR
- 74% (29%-82%)
- TAR
- 25% (18%-71%)
- TBR
- 1% (0%-5%)
Safety
Adverse events
- Ketoacidosis caused by infusion set failure
- 1 person
- Severe hypoglycemia
- 0
Original publication
GLP-1 Receptor Agonists in Overweight and Obese Individuals With Type 1 Diabetes Using an Automated Insulin Delivery Device: A Real-World Study. J Diabetes Sci Technol. Published 17 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →